Published Online
on July 28, 2003

A more recent version of this article appeared on September 1, 2003

This Article Full Text (PDF) All Versions of this Article: 42/3/373    most recent 01.HYP.0000084633.85427.E6v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watson, A. M.D. Articles by May, C. N. Search for Related Content PubMed PubMed Citation Articles by Watson, A. M.D. Articles by May, C. N. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB EPINEPHRINE Related Collections Autonomic, reflex, and neurohumoral control of circulation

Submitted on March 31, 2003
Revised on April 21, 2003

Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions

Anna M.D. Watson; Gavin W. Lambert; Kathryn J. Smith; and Clive N. May^*

From the Howard Florey Institute, University of Melbourne (A.M.D.W., K.J.S., C.N.M.), and the Baker Heart Research Institute (G.W.L.), Prahran, Melbourne, Victoria, Australia.

^* To whom correspondence should be addressed. E-mail: c.may{at}hfi.unimelb.edu.au.

Abstract--Urotensin II is a small peptide whose receptor was recently identified in mammals as the orphan G protein-coupled receptor-14. The reported cardiovascular responses to systemic urotensin II administration are variable, and there is little detailed information on its central cardiovascular actions. We examined the cardiovascular and humoral actions of intracerebroventricular urotensin II (0.02 and 0.2 nmol/kg and vehicle) and intravenous urotensin II (2, 20, and 40 nmol/kg and vehicle) in conscious ewes previously surgically implanted with flow probes and intracerebroventricular guide tubes. Two hours after intracerebroventricular infusion of urotensin II (0.2 nmol/kg over 1 hour; n=5), heart rate (+56±13 beats per minute [bpm]), dF/dt (an index of cardiac contractility; +533±128 L · min^-1 · s^-1), and cardiac output (+3.4±0.4 L/min) increased significantly compared with vehicle, as did renal, mesenteric, and iliac blood flows and conductances. Plasma epinephrine, adrenocorticotropic hormone, and glucose levels also increased dramatically (+753±166 pg/mL, +14.3±3.5 pmol/L, and +7.0±1.4 mmol/L, respectively). All of these variables remained elevated for up to 4 hours after infusion. In contrast, 1 hour after intravenous urotensin II (40 nmol/kg bolus; n=6), a sustained tachycardia (+25±8 bpm) ensued, but cardiac output, cardiac contractility, total peripheral conductance, and plasma glucose levels did not change significantly. In summary, this is the first study to show that urotensin II acts centrally to stimulate sympathoadrenal and pituitary-adrenal pathways, resulting in increased adrenocorticotropic hormone and epinephrine release and potent chronotropic and inotropic actions. In contrast, tachycardia was the only major response to intravenous urotensin II. These findings suggest that urotensin II is a novel stimulator of central pathways that mediate responses to alerting stimuli or stress.

Key words: cardiac output • adrenocorticotropic hormone • glucose • hemodynamics • urotensin • sheep

This article has been cited by other articles:

				P. N. Sidharta, P. L. M. van Giersbergen, and J. Dingemanse Pharmacokinetics and Pharmacodynamics of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects J. Clin. Pharmacol., October 1, 2009; 49(10): 1168 - 1175. [Abstract] [Full Text] [PDF]

				U. Bicak, H. Karabiber, H. I. Ozerol, M. Aslan, A. Ilhan, and C. Yakinci Possible Pathogenic Link Between Migraine and Urotensin-II J Child Neurol, November 1, 2008; 23(11): 1249 - 1253. [Abstract] [PDF]

				S. G. Hood, T. Cochrane, M. J. McKinley, and C. N. May Investigation of the mechanisms by which chronic infusion of an acutely subpressor dose of angiotensin II induces hypertension Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2007; 292(5): R1893 - R1899. [Abstract] [Full Text] [PDF]

				M. Clozel, P. Hess, C. Qiu, S.-S. Ding, and M. Rey The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1115 - 1121. [Abstract] [Full Text] [PDF]

				E. Cowley, J. P. Thompson, P. Sharpe, J. Waugh, N. Ali, and D. G. Lambert Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study Br. J. Anaesth., October 1, 2005; 95(4): 495 - 499. [Abstract] [Full Text] [PDF]